Sign In
Buy SLP
$16.17
-0.600 (-3.58%)
At Close: Jun 03, 2026
SLP's Q3 Earnings Top, Sales Up Y/Y, Stock Gains Despite Lowered View
10:20am, Tuesday, 15'th Jul 2025
Simulation Plus' fiscal Q3 2025 earnings surge 67% on Pro-ficiency gains, but a cut in 2025 outlook shows hurdles in biosimulation and services.
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
08:40am, Tuesday, 15'th Jul 2025
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Tuesday.
Simulations Plus, Inc. (SLP) Q3 2025 Earnings Call Transcript
08:29pm, Monday, 14'th Jul 2025
Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2025 Earnings Conference Call July 14, 2025 5:00 PM ET Company Participants Shawn M. O'Connor - Chief Executive Officer William Frederick - EVP & CFO Conference
Simulations Plus Invests in Clinical Development Technology Company Nurocor
04:15pm, Monday, 14'th Jul 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and i
Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results
04:05pm, Monday, 14'th Jul 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enab
Simulations Plus (SLP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:00am, Monday, 07'th Jul 2025
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call
04:05pm, Wednesday, 18'th Jun 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enab
52-Week Lows? No Problem for 3 Stocks With Big Upside Potential
07:58am, Tuesday, 17'th Jun 2025
Companies trading at or near 52-week lows often send skittish investors running. After all, a basic tenet of momentum investing is that, without a change in business fundamentals or external circumsta
Simulations Plus: Further Downside Is Likely (Rating Downgrade)
08:45am, Friday, 13'th Jun 2025
Simulations Plus' Q3 FY25 results missed expectations, with revenue guidance cut sharply due to biopharma market weakness and services segment volatility. Organic growth continues to decelerate and th
Simulations Plus Slashes Guidance Amid Biotech Spending Cuts, Analyst Expresses Doubt
02:15pm, Thursday, 12'th Jun 2025
Simulations Plus Inc SLP stock tanked after the company lowered its fiscal 2025 sales outlook.
SLP Cuts FY25 Revenue Outlook, Begins Strategic Reorganization
11:21am, Thursday, 12'th Jun 2025
Simulations Plus lowers FY25 revenue forecast and restructures operations as biotech headwinds hit services demand.
Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum
07:50am, Thursday, 12'th Jun 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled perfor
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
04:30pm, Wednesday, 11'th Jun 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enab
Simulations Plus Releases ADMET Predictor® 13
07:50am, Thursday, 05'th Jun 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and i
SLP Advances Predictive Toxicology With DILIsym 11: Shares to Benefit?
09:30am, Monday, 19'th May 2025
Simulations Plus unveils DILIsym 11, an upgraded version of its flagship QST platform to advance predictive toxicology and pediatric liver assessment safety.
